WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

*Dr. Noor Ghalib Othman and Dr. Mohsin A. Sahib

ABSTRACT

Background: For its safety, reliability, and speed, fine-needle aspiration cytology (FNAC) is often used to assess breast lumps outdoors. Recently, breast lesions are largely diagnosed by Tru-cut biopsies and fine-needle aspiration cytology is decreasing. The present study was undertaken to compare the diagnostic accuracy of Tru-cut Biopsy and Fine Needle Aspiration Cytology (FNAC) in the evaluation of screen- detected breast lesion considering the histological diagnosis from excision specimen being the gold standard. Methods: From February 2021 to January 2023, the Department of Oncology, Oncology Teaching Hospital, Baghdad medical city, Baghdad, Iraq, performed this cross-sectional research. The research sequentially included 80 women with screen-detected breast lesions. All patients had FNAC and Tru-cut Biopsy to establish a preliminary (clinical) breast lump diagnosis, followed by histology of the excision biopsy during surgery to confirm it. Results: 80 breast lesions-afflicted women aged 55 ± 13 years. 41% of 60+ patients. 90% of women with FNA breast cancer. Breast cancer is diagnosed by core and excisional biopsy in 93.8% of women. No-type invasive ductal carcinoma was most prevalent. FNA is related with core and excisional biopsy in 94.6% of diagnosed breast cancer women. 60% of benign breast disease (core & excisional biopsy) patients had FNA-diagnosed proliferative with atypia. 100% of breast cancer patients over 50 get excisional biopsy. 100% of core biopsy-diagnosed malignant breast cancer patients got excisional biopsy. sensitivity, specificity, and accuracy 100% Conclusion: The research found significant diagnostic concordance between FNA and combined biopsy for malignant breast illnesses, with age being a key factor, particularly for women over 50. Core and excisional biopsy procedures match, demonstrating unsurpassed cancer detection accuracy.

[Full Text Article] [Download Certificate]